Circulating miRNAs have shown great promises as noninvasive diagnostic and predictive biomarkers in several solid tumors. While the miRNA profiles of renal tumors have been extensively explored, knowledge of their circulating counterparts is limited. Our study aimed to provide a large-scale genome-wide profiling of plasma circulating miRNA in clear-cell renal cell carcinoma (ccRCC). Plasma samples from 94 ccRCC cases and 100 controls were screened for 754 circulating micro-RNAs (miRNA) by TaqMan arrays. Analyses including known risk factors for renal cancer-namely, age, sex, hypertension, obesity, diabetes, tobacco smoking and alcohol consumption-highlighted that circulating miRNA profiles were tightly correlated with the stage of the disease. Advanced tumors, characterized as stage III and IV, were associated with specific miRNA signatures that significantly differ from both controls and earlier stage ccRCC cases. Molecular pathway enrichment analyses of their gene targets showed high similarities with alterations observed in renal tumors. Plasma circulating levels of miR-150 were significantly associated with RCC-specific survival and could marginally improve the predictive accuracy of clinical parameters in our series, including age at diagnosis, sex and conventional staging. In summary, our results suggest that circulating miRNAs may provide insights into renal cell carcinoma progression.
Worldwide, more than 337,000 cases of renal cancer are diagnosed each year, leading to over 143,000 deaths annually. 1 The most common histological subtype of renal cancer is clear cell renal cell carcinoma (ccRCC) which accounts for 70-80% of sporadic cases and for the majority of renal cancer mortality. 2 While nephrectomy is used as standard firstline treatment for localized RCC, a substantial proportion of cases develop metastatic disease, which has very poor prognosis. Moreover, early-stage RCC is typically asymptomatic, frequently leading to delayed diagnosis, often at advanced stages with limited therapeutic options. 3 Noninvasive methods to improve the detection, prognosis and monitoring of renal cancer are much needed. MicroRNAs (miRNAs) are a group of short noncoding RNAs that regulate gene expression at the posttranscriptional level. Aberrant expression of miRNAs is an established feature of human malignancy and has been associated with oncogenesis and tumor progression. 4 Recent studies have demonstrated that miRNAs are detectable in body fluids, including blood. 5 Given their ease of access and stability, circulating miRNAs show great promise as novel minimally invasive biomarkers. While differences in the miRNA profiles of tumors versus adjacent renal tissues have been extensively explored, 6, 7 only a few studies have assessed circulating levels of miRNA in the blood of RCC patients, often through candidate miRNA approaches. [8] [9] [10] [11] [12] [13] [14] There was no obvious overlap between the circulating miRNA signatures obtained from the three genome-wide studies performed to date, but screening was limited to small numbers of samples (6, 15 and 25 RCC patients respectively). [15] [16] [17] Those studies used serum samples, while recent literature suggests that the composition of circulating miRNAs may be altered by coagulation. 18 Here we present the results from a genome-wide miRNA profiling of plasma samples from 94 RCC patients and 100 noncancer controls, with the objective to assess the potential of circulating miRNAs as diagnostic and prognostic biomarkers.
Material and Methods

Study population
Recruitment for this case-control study was conducted between 2006 and 2012. Incident ccRCC cases were prospectively recruited from the Russian N.N. Blokhin Cancer Research Centre and Moscow City Clinical Oncology Dispensary. Controls were individuals visiting two Moscow general hospitals for disorders unrelated to kidney cancer and associated risk factors. A unique set of controls was selected to fit this study and a parallel study of non-small-cell lung cancer from the same area. 19 All study participants provided written informed consent. All specimens were obtained in accordance with the declaration of Helsinki, with the approval of local Institutional Review Board and the IARC Ethics Committee. A total of 94 ccRCC cases and 100 controls were included in the analyses. Plasma samples were collected before any cancer therapy and systematically processed following a standardized protocol. In brief, peripheral blood was collected in EDTA tubes at the time of interview and processed within 2 hr. Plasma samples were recovered after centrifugation of whole blood at 2,000g for 10 min at room temperature. Samples were stored at 2808C until use.
RNA isolation
Total RNA was isolated from 300 lL of plasma using NucleoSpin V R miRNA Plasma kit (Macherey-Nagel, D€ uren, Germany). All samples were spiked-in with 10 pmol of Arabidopsis thaliana synthetic miR-159a (synthesized by Eurofins MWG Operon, Ebersberg, Germany) to control for variations in the RNA preparation step.
Profiling by TaqMan human MicroRNA arrays
Expression levels of 754 miRNAs (Sanger miRBase v14) were quantified using the TaqMan Human MicroRNA Array A 1 B Card Set v3.0 (Applied Biosystems, Foster City, CA) as per the manufacturer's instructions. TaqMan MicroRNA Arrays were run on an ABI 7900HT Real-Time PCR platform. Quantitative miRNAs expression data were acquired by ABI 7900HT SDS software v2.4. Cycle threshold (Ct) values were set using ExpressionSuite software (Applied Biosystems) on the first 60 samples (automatic baseline and threshold) and these thresholds for Ct were used for the remaining series.
Statistical analysis
All analyses were performed by using R version 3.1.2. 20 Descriptive comparisons of study variables between cases and controls used the Pearson chi-squared test for categorical data, and Student's t test for continuous data.
Differential expression analyses were performed using R Bioconductor HTqPCR package. 21 Any miRNA with undetermined Ct values in more than 120 samples was excluded.
Several data normalization strategies were tested including quantile, deltaCt, geometric mean, rank invariant normalization and normalization to endogenous U6snRNA control, and to a combination of let-7d, let-7g and let-7i as recently suggested by Wang et al. 17 Ct values with an interquartile range (IQR) of <1.5 and controls (snU6, ath-miR-159a) were filtered out from subsequent analysis. The identification of differentially regulated miRNA between cases and controls was based on limma analysis. Logistic regression models included known or suspected risk factors for ccRCC, namely, age at diagnosis, sex, medical history of hypertension, BMI 2 years prior to diagnosis, tobacco-smoking status (never, former or current smoker), alcohol consumption status (never, former or current alcohol drinker), and medical history of diabetes. A multiple testing correction with the Benjamini-Hochberg procedure was used to control the false discovery rate at 5% (q values <0.05).
To estimate a minimally redundant multimarker panel of miRNAs discriminating cases from controls, we performed a penalized logistic regression with the Lasso penalty, adjusting for known ccRCC risk factors, as defined above, using 10-fold cross-validation to tune the penalty parameter. Lassopenalized regression is specifically designed for variable selection in large high-dimensional data, and is applicable even when the number of dimensions is larger than the sample size. The percentile approach of Roberts and Nowak was applied to optimize the stability of our model. 22 Predictive performance was assessed by the area under the receiver operating characteristic curve (AUC), with 95% confidence intervals (CI). Internal validation consisted in calculating the bootstrap optimism-corrected AUC 23 to account for overfitting of the model parameters, and by bootstrapping the entire model selection process (model selection and parameters estimation). The R package miRNApath (Pathway Enrichment for miRNA Expression Data) v1.31.0 was used to identify What's new? Early-stage renal cell carcinoma (RCC) frequently is asymptomatic. As a consequence, patients may not be diagnosed until late in the disease course, when risk for poor prognosis is increased. A promising avenue toward improving RCC detection and patient management is through the identification of noninvasive diagnostic and prognostic markers. Here, genome-wide profiling of plasma circulating microRNAs (miRNAs) uncovered miRNAs associated with advanced RCC and survival. The data show that while levels of a single miRNA-miR-150-were significantly associated with RCC survival, no panel of miRNAs was able to discriminate early-stage cases from controls more effectively than existing clinical parameters. molecular pathways overrepresented among genes associated with differentially expressed miRNAs. 24 Experimentally supported miRNA targets were retrieved from TarBase v7.0, 25 and their corresponding pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG), release 73.0 (301 human specific pathways). 26 Statistical significance was assessed by permutation tests with 2,500 replicates.
Overall survival and disease-specific survival were measured from the date of diagnosis to the date of death from any cause or death from RCC, respectively. Survival probabilities were estimated by using the Kaplan-Meier method, with log-rank test for comparison of the outer quartiles. Progression-free survival (PFS) was measured in cases who did not present metastasis at diagnosis, from the date of surgery to the date of development of metastasis, if any, or death from any cause. Cox proportional hazards regression models were used to estimate log-hazard ratios per Ct value, and were adjusted for stage of the disease, sex and age. All covariates were confirmed to satisfy the proportional hazards assumption by assessing Schoenfeld residuals. Panels of miRNA predictors of outcome were estimated using Lasso-penalized Cox regression, following the same strategies of stabilization and optimism correction described above for the case-control comparison.
Results
Study population
The characteristics of 194 study participants, including 94 ccRCC patients and 100 controls, are presented in Table 1 . CcRCC patients included 39 stage I and 10 stage II cases, subsequently defined as early-stage cases (n 5 49), as opposed to 25 stage III and 20 stage IV cases, referred to as late-stage cases (n 5 45). In line with our study design, there were significant differences in sex, alcohol status, smoking status and hypertension between cases and controls (Table 1) . While no differences were observed between late-stage cases and controls, early-stage cases were less likely than controls to be male, to have a history of hypertension and to consume alcohol or tobacco. The average follow-up time for ccRCC patients was 4 years, ranging from 1 to 94 months, with 40 death events, including 35 due to renal tumor.
Micro-RNA profiles in plasma
To evaluate whether specific miRNA signatures were detectable in plasma samples of patients with ccRCC, a TaqMan-based high-throughput screen of 754 miRNAs was performed. A total of 232 and 113 miRNAs were detected on Card A and Card B, respectively. MiRNAs previously described as readily detectable in human plasma samples-including hsa-let-7a, hsa-miR-16 and hsa-miR-21-were detected in all samples. Given that the normalization of miRNA data in plasma samples is still a controversial issue, several data normalization strategies were tested. Based on exploratory data analysis plots and instability of endogenous controls, quantile normalization was applied.
Following IQR filtering, a total of 288 miRNAs were subjected to differential expression analyses. Of those, 44 miRNAs were found to be significantly differentially expressed between ccRCC cases and controls after adjusting for known risk factors, namely, age, sex, BMI, diabetes, hypertension, alcohol consumption status and smoking status (Supporting Information, Table 1 ), but none remained significant after multiple testing corrections. When including the 288 miRNAs in a Lassopenalized model adjusted for known ccRCC risk factors, two miRNAs (miR-451 and miR-26b#) were found to discriminate cases from controls, with an apparent AUC of 0.80 [95% CI 5 0.73-0.86]. Taking into account overfitting in parameters estimation gave an AUC of 0.75, down to 0.64 when considering the entire selection process. The classification solely based on known ccRCC risk factors showed an AUC of 0.74 [95% CI 5 0.67-0.81] (Fig. 1) , estimated at 0.69 after correction for optimism in parameters estimation. The 2-miRNA panel was not redundant with known ccRCC risk factors, as suggested by the significant difference observed when adding miR-451 and miR-26b# to the model (p 5 4.9e-5, likelihood ratio test).
While no miRNA could significantly distinguish between early-stage ccRCC and noncancer controls, a set of 60 miRNAs was significantly differentially expressed in late-stage ccRCC compared with controls after multiple testing corrections (Table 2) . Similarly, a set of 27 miRNAs was significantly differentially expressed in late-stage versus early-stage ccRCC ( Table 2 ). All but 5 also differed from controls ( Table  2) . None of the miRNAs overexpressed in late-stage ccRCC were among the 119 miRNAs most commonly found in serum and plasma. 27 
Pathway analysis
Pathway enrichment analyses with permutation tests were used to identify the molecular pathways significantly altered Figure 1 . Evaluation of the performance of classifiers of ccRCC cases versus non-cancer controls based on the assessment of the area under receiver operating characteristics (ROC) curves (AUCs). by coordinated changes in miRNAs expression, restricting the analyses to experimentally validated miRNAs targets extracted from TarBase. The gene targets of the 60 miRNAs that were differentially expressed in late-stage ccRCC cases compared with controls were significantly enriched in pathways related to metabolism, and Notch and ErbB signaling pathways (Table 3) . Metabolic pathways included glycolysis and the biosynthesis/metabolism of nucleotides, amino acids, vitamins such as vitamin B6 and fatty acids. Molecular targets involved in the pathogenesis of diabetes were also overrepresented, and so was the only known metabolic pathway associated with ccRCC, hypoxia-inducible factor-1 (HIF-1) signaling. Pathway enrichment analyses from the set of 27 miRNAs discriminating late-stage from earlier stage ccRCC highlighted similar pathways, but also base excision repair, nucleotide excision repair and DNA replication.
Cancer Epidemiology
The genes most recurrently targeted by the miRNAs differentially expressed in late-stage ccRCC included avian myelocytomatosis viral oncogene homolog (MYC) and a number of its targets, like cyclin D1 (CCND1), the vascular endothelial growth factor A (VEGFA) and other genes from PI3K-Akt pathway, including insulin-like growth factor-I receptor IGF1R and cyclin-dependent kinases CDKN1A and CDK6 (Supporting Information, Table 2 ).
Prognosis markers analysis
Survival of RCC patients was strongly driven by the stage of the disease. After correction for multiple testing, only miR-150 and miR-587 were significantly associated with diseasespecific survival (q 5 0.004 and q 5 0.03, respectively), miR-150 being also associated with overall survival (q 5 0.03). Likelihood ratio tests comparing models including stage, age and sex, with or without either miRNA, suggested that only miR-150 was not redundant with known characteristics Cases with lower circulating levels of miR-150 had a median survival of 10 months compared with 64 months for cases with higher miR-150 circulating levels (Fig. 2) . A total of 29 cases had metastasis at diagnosis (n 5 19) or developed metastases during follow-up (n 5 10). After multiple testing correction, there was no significant association between the presence, nor the development, of metastasis and the expression levels of individual circulating miRNA, including for miR-150 ( Supporting Information, Fig. 1 ). Lassopenalized Cox regressions for PFS, adjusted for age, sex and disease stage, selected 3 miRNAs (miR-876-3p, miR-487a and miR-15a). However, after bootstrap optimism corrections accounting for the entire selection process, we found that these miRNAs were unlikely to substantially improve prediction of PFS. 
Discussion
No consistent circulating miRNA signatures of renal cancer have yet emerged from the literature. We screened plasmacirculating miRNAs of 94 ccRCC cases, along with 100 controls, in what is, to our knowledge, the largest exploratory study of renal cancer plasma circulating miRNA reported to date. In our series, no panel of miRNAs was able to discriminate cases from controls better than known or suspected risk factors for renal cancer, including age, sex, obesity, diabetes, hypertension, tobacco smoking and alcohol consumption. In contrast, advanced tumors of stage III and IV showed specific miRNA profiles that significantly differ from both controls and cases at stage I and II, suggesting that our ability to detect ccRCC from circulating miRNA expression levels depends on the advancement of the disease. Our results provide a possible explanation for some of the observed discrepancies among earlier studies in which staging was not systematically considered. They also emphasize the need for careful study design and data interpretation in exploratory phases, assessing the value of circulating miRNA expression levels for early detection of kidney cancer. Similar to the study by Redova et al., we observed that miR-451 had the highest discriminatory power in terms of predicting case-control status. 16 In our series, miR-451 was significantly underexpressed in the plasma of stages III and IV ccRCC cases compared with both controls (|FC| 5 6.4; q 5 3.8e-8) and earlier stages ccRCC cases (|FC| 5 6.1; q 5 3.0e-6), suggesting a link with the progression of the disease rather than its onset. MiR-451 is widely dysregulated in tumor tissues. 28 Recent studies underline the critical role of miR-451 in the progression of multiple myeloma and glioblastoma, with tumor suppressive effects mediated by the Pi3K/Akt/mTOR signaling pathway. 29, 30 We and others have showed that Pi3K/Akt pathway is recurrently affected by abnormal gene expression patterns in ccRCC. [31] [32] [33] Downregulation of miR-451 in ccRCC tumor tissues was unveiled as part of an miRNA signature that distinguished metastatic cases. 34 Besides, miR-451 was found to be one of the most highly represented miRNA with tumor suppressor activity in the blood of healthy individuals, 35 triggering the hypothesis that it could mediate a tumor-surveillance mechanism complementing immune surveillance. Shutting down such safeguards may also contribute to tumor progression.
Pathways overrepresented among the gene targets of the 60 circulating miRNAs discriminating late-stage ccRCC cases from controls showed strong overlaps with those of differentially expressed genes in renal tumors, 31 including Pi3K/Akt, ErbB and HIF-1. The most recurrent genes targeted by those miRNAs included MYC oncogene, known to act together with HIF factors to fine tune the metabolic adaptation to hypoxic environment and promote tumor growth, 36 and key HIF-responsive genes, such as VEGFA and CCDN1. 37 Constitutive upregulation of HIF-1 resulting from VHL loss of function is a hallmark of RCC 38 and is critical for cancer progression, especially through metabolic reprogramming allowing tumor cells to adapt to a low-oxygen environment. 39 This suggests that a good proportion of the observed changes in the plasma are indeed originating from the tumor. Pathway enrichment analyses in the late-stage ccRCC also highlighted multiple metabolism-related signaling, including vitamin B6 metabolism. We have shown in three independent cohorts that plasma concentration of vitamin B6 correlates with RCC risk and prognosis, 40, 41 conferring differential survival including to advanced cases. 41 Multiple pathways implicated in tumor development directly or indirectly depend on vitamin B6, including cell proliferation, angiogenesis and oxidative stress, as demonstrated in colon tumorigenesis. 42 Whether miRNAs may contribute to regulate any of the metabolic determinants of circulating vitamin concentrations remains to be investigated.
In our series, there were no significant differences in plasma circulating miRNA expression levels between stage I or II ccRCC cases and controls, unlike two recent reports that suggested serum circulating miRNAs as potential diagnostic biomarkers, using a similar qRT-PCR methodology. Wang et al. described a 5-miR panel that distinguished stage I RCC from controls. 17 This included upregulated serum levels of miR-193a-3p, miR-362 and miR-572 and downregulated miR-28-5p and miR-378 identified through a screening set of 25 RCC versus 25 controls. In contrast, in their large series of 195 RCC of various subtypes, most of them ccRCC (n 5 157) and from early-stage disease (n 5 133), Fedorko et al. showed that an increased expression of serum circulating miR-378 and miR-210 could distinguish RCC cases from controls (n 5 100) with 80% sensitivity and 78% specificity. 13 We observed no significant differences in the expression of plasma circulating miR-378 in our series of early stage RCC Figure 2 . Kaplan-Meier estimates of disease-specific survival in patients with ccRCC according to the expression levels of plasma circulating miR-150. Overall, ccRCC cases with low levels of circulating miR-150 (quartile with the highest Ct values) were associated with shorter RCC-specific survival (*indicates the p value of the log-rank test).
cases, despite a similar distribution of stage I versus Stage II (40 versus 11) compared with the extended validation set of Wang et al. (76 versus 16) . 17 Variability in serum expression levels of miR-378 and other miRNAs has been previously described, 12, 18 highlighting critical factors, such as the impact of coagulation, sample collection and normalization methods. While the use of plasma in our study is a strength to prevent bias related to RNA release during coagulation process, normalization issues cannot be ruled out. Nevertheless, we carefully tested multiple data normalization strategies and applied quantile normalization to overcome the issues of classical reference genes, recurrently underlined as leading to inconsistent variations when used for the relative quantification of circulating miRNAs. 43 Finally, we investigated whether circulating miRNAs could represent a noninvasive alternative to the recently suggested panels of tumor miRNAs as prognostic biomarker. 6, [44] [45] [46] Although no miRNA signature could robustly predict progression free survival, lower plasma circulating levels of miR-150 were significantly associated with both overall and RCCspecific survival (q 5 0.03 and q 5 0.004, respectively). Stringent comprehensive internal validation suggested that plasma levels of miR-150 may be of interest for prognostic predictions in ccRCC. MiR-150 prognostic value was not redundant with age, sex and conventional staging and could marginally improve their predictive accuracy in our series (bootstrap optimism-corrected AUC of 0.81 versus 0.78). Highly expressed in mature B and T cells, miR-150 plasma levels correlate with lymphoid cells count. 47 Downregulation observed in circulating miR-150 of ccRCC cases may reflect a blood cell-based effect, related to impaired immune response or consequences of cancer treatment. 47 Of note, ccRCC cases screened here had not yet received any treatment. Besides, recent studies on colon cancer and hepatocellular carcinoma showed that low circulating miR-150 levels were associated with advanced disease and shortened overall survival. 48, 49 Functional studies are warranted to understand miR-150 underlying molecular mechanisms specifically in RCC.
In conclusion, while our results do not support the use of plasma miRNAs as early-detection markers in ccRCC, they contribute evidence that circulating miRNAs are associated with the progression of renal carcinoma. Plasma miRNA signatures specifically associated with late-stage disease may yield further insights into ccRCC pathogenesis and contribute to disease monitoring.
